155 related articles for article (PubMed ID: 1638541)
1. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.
Lattime EC; Gomella LG; McCue PA
Cancer Res; 1992 Aug; 52(15):4286-90. PubMed ID: 1638541
[TBL] [Abstract][Full Text] [Related]
2. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
[TBL] [Abstract][Full Text] [Related]
3. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
4. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
5. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
8. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
9. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
11. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
12. Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin-induced granuloma formation in mice lacking CD4 and CD8.
Senaldi G; Shaklee CL; Mak TW; Ulich TR
Cell Immunol; 1999 May; 193(2):155-61. PubMed ID: 10222057
[TBL] [Abstract][Full Text] [Related]
13. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells.
Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM
Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825
[TBL] [Abstract][Full Text] [Related]
15. Novel insights into the mechanism of action of intravesical immunomodulators.
Mitropoulos DN
In Vivo; 2005; 19(3):611-21. PubMed ID: 15875784
[TBL] [Abstract][Full Text] [Related]
16. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
Biot C; Rentsch CA; Gsponer JR; Birkhäuser FD; Jusforgues-Saklani H; Lemaître F; Auriau C; Bachmann A; Bousso P; Demangel C; Peduto L; Thalmann GN; Albert ML
Sci Transl Med; 2012 Jun; 4(137):137ra72. PubMed ID: 22674550
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene.
Wojciechowski W; DeSanctis J; Skamene E; Radzioch D
J Immunol; 1999 Sep; 163(5):2688-96. PubMed ID: 10453010
[TBL] [Abstract][Full Text] [Related]
18. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
Bunimovich-Mendrazitsky S; Byrne H; Stone L
Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
[TBL] [Abstract][Full Text] [Related]
19. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
20. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
